THOUSAND OAKS, Calif., May 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 88 percent of outstanding shares were represented at the meeting.
The director nominees David Baltimore, Frank J. Biondi, Jr., Robert A. Bradway, François de Carbonnel, Vance D. Coffman, Robert A. Eckert, Greg C. Garland, Rebecca M. Henderson, Frank C. Herringer, Tyler Jacks, Judith C. Pelham, and Ronald D. Sugar were each re-elected to Amgen's Board of Directors. Each director received at least 90 percent of the votes cast "For." Gilbert S. Omenn is retiring from the Board. With the re-election of all of the director nominees, and the retirement of Dr. Omenn, Amgen currently has 12 directors.
With approximately 98 percent of the votes cast "For," stockholders ratified Ernst & Young LLP as Amgen's independent registered public accountants for the year ending Dec. 31, 2014.
Stockholders approved, on an advisory basis, the named executive officer compensation, commonly known as "Say on Pay." The non-binding proposal gives stockholders the opportunity to endorse or not endorse Amgen's executive pay programs and policies. Say on Pay received approximately 97 percent of the votes cast "For" the proposal.About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.